CHICAGO and ATLANTA, December 11, 2019 — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced the acquisition of AKESOgen, an industry-leading commercial laboratory facility and provider of genomics and clinical trial precision medicine services based in Atlanta.
AKESOgen is an integrated genomics, genetics, and biobanking company that works with the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. The acquisition bolsters Tempus’ expansion into disease areas outside of cancer and provides strategic capabilities beyond its own lab in Chicago. AKESOgen’s Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited lab offers a range of testing services, including inherited risk for cancer, microbiome profiling, whole genome genotyping, and epigenomic methylation profiling.
“We’re thrilled to have AKESOgen join the Tempus team,” said Eric Lefkofsky, Founder & CEO of Tempus. “AKESOgen’s breadth of capabilities strategically complement our own, and we look forward to bringing the power of data and artificial intelligence to healthcare and advancing the field of precision medicine together.”
“We are delighted to be a part of Tempus’ data driven precision medicine mission,” commented Robert Boisjoli, CEO of AKESOgen. “Utilizing scaled multi-omics approaches will ultimately reap benefits for 21st Century medicine and we are extremely excited to be a part of this endeavor.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitate discovery, development and delivery of optimized therapeutic options for patients through distinctive solution sets. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
AKESOgen is an integrated CLIA-compliant and CAP-accredited genomics, genetics and bio-banking company that works with the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, AKESOgen’s services include providing high-throughput biomarker profiling, microarray, sequencing, genomics, microbiome and epigenomics analysis utilizing different types of markers. For more information, visit www.akesogen.com.